Biotech Values

[cfoofme]

NanoViricides, Inc. Finds FluCide(TM)-I Superior to Oseltamivir in Preliminary Animal Studies, Presents Data at the 7th Annual Targeted Nano-delivery Conference
A Company to Release Financials at the End of This Week
PrintE-mailDisable live quotesRSSDigg itDel.icio.usLast Update: 12:52 PM ET Oct 18, 2006


WEST HAVEN, Conn., Oct 18, 2006 (BUSINESS WIRE) -- NanoViricides (Pink Sheets: NNVC) President and Chairman, Dr. Anil Diwan, presented preliminary data on animal studies that compare nanoviricides drug candidates with oseltamivir (Tamiflu(R) Roche) on Friday, Oct. 13th at the 7th Annual Targeted Nano-delivery Conference in Baltimore, MD.
"Mice treated with the FluCide(TM)-I nanoviricide drug survived 186 hours (7.75 days, or 2.75 days more than control mice), whereas those treated with oseltamivir at twice the usual amounts normally used in such studies survived for only 151 hours (6.3 days, or only about 1.3 days longer than control). The experiment was designed with an aggressive infection level of common influenza such that control mice survived only 120 hours (5.0 days)," Dr. Diwan reported at the Conference. He also reported that all nanoviricides drug candidates tested were found to be superior to oseltamivir in this study. The studies were conducted by Dr. Krishna Menon under the auspices of KARD Scientific, Inc. in a blind study at a facility in Cambridge, MA. Dr. Mennon commented, "No obvious toxic effects were observable for the nanoviricide drugs. Therefore we believe the dosage of the nanoviricide drugs can be substantially increased to their therapeutic levels. This is expected to lead to a greatly enhanced therapeutic effect. This test was designed only to establish comparative baselines. Future experiments will be designed to assess the full therapeutic dosage levels and their efficacies."
NanoViricides, Inc. believes that at present no other anti-influenza drug candidate has shown results that are anywhere close to the results obtained with nanoviricides, both in terms of the in vitro data in H5N1 (presented earlier) and the in vivo data against common influenza.
In other news, NanoViricides announced it is on target to release its financials by the end of this week.
About NanoViricides - http://www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricide drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
SOURCE: NanoViricides, Inc.